Women at high risk of developing preterm preeclampsia (≤37 weeks) are identified through a first-trimester screening test incorporating maternal characteristics, mean arterial blood pressure, uterine artery pulsatility index, and maternal serum analytes, such as pregnancy-associated plasma protein-A (PAPP-A) and placental growth factor (PlGF) [29]. The gene discussed is PGF; the disease is preeclampsia.